Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Tuesday, February 1, 2011

Biotech/Pharma Stocks News; UV Flu Technologies to Become an Official Equipment Supplier to Hockey Canada

CENTERVILLE, MA � February 1, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's athletic distributor, New England Sports Sales ("NESSI"), a national distributor of hockey and related athletic equipment to college and professional hockey teams across the US and Canada, has been notified that they will be facilitating the shipment of ViraTech UV-400 air purifiers to the Hockey Canada practice and training facility in Calgary.
The WinSport Canada facility operates under the scope of Hockey Canada, the national body regulating the sport across Canada. Located in Calgary's Canada Olympic Park, the 500,000-square-foot structure currently includes three North American-size ice rinks designed for hockey, sledge hockey as well as figure skaters. The facility has already been dubbed a calling card for Calgary in continuing to attract world-class athletes to the city.
With this shipment, scheduled for delivery upon completion of the facility, UV Flu will become an official supplier to Hockey Canada, and will continue to build brand awareness within the sport by directly introducing the product to the athletes who will benefit the most by its use. Hockey Canada will be an excellent addition to the growing list of teams and facilities utilizing the product including the Boston Bruins, Pittsburgh Penguins, and several notable college organizations.
"We believe we have not even scratched the surface for the potential demand of this product in the professional and college athletic marketplace," commented Charles Gulteri, President of NESSI. "Hockey and basketball are major sports where every player is critical to the team and the constant travel and changing weather conditions during cold and flu season create fertile conditions for the spread of illness. The UV-400 will prevent the spread of many of these airborne illnesses for an incredibly low price and we believe teams cannot afford to be without them in their team areas. We plan on talking with the NHL, as well as college teams, to further educate them on the importance of this product," said Mr. Gulteri.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

No comments:

Post a Comment